MiNK Therapeutics (INKT) News Today → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free INKT Stock Alerts $0.97 +0.01 (+1.04%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 22, 2024 | finanznachrichten.deMiNK Therapeutics: MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual MeetingMay 22, 2024 | globenewswire.comMiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual MeetingMay 15, 2024 | uk.finance.yahoo.comQ1 2024 Mink Therapeutics Inc Earnings CallMay 15, 2024 | finance.yahoo.comMiNK Therapeutics Inc (INKT) Q1 2024 Earnings Call Transcript Highlights: Strategic Reductions ...May 14, 2024 | investorplace.comINKT Stock Earnings: MiNK Therapeutics Beats EPS for Q1 2024May 14, 2024 | globenewswire.comMiNK Reports First Quarter 2024 ResultsMay 13, 2024 | globenewswire.comMiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board ObserverApril 30, 2024 | finance.yahoo.comMiNK to Provide Corporate Update and First Quarter 2024 Financial ReportApril 30, 2024 | globenewswire.comMiNK to Provide Corporate Update and First Quarter 2024 Financial ReportApril 11, 2024 | finance.yahoo.comThis MiNK Therapeutics Insider Increased Their Holding In The Last YearApril 8, 2024 | globenewswire.comMiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACRMarch 25, 2024 | markets.businessinsider.comBuy Rating for MiNK Therapeutics Amidst Promising AGENT-797 Progress and Strategic Financial MovesMarch 22, 2024 | insidermonkey.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | markets.businessinsider.comPromising Clinical Progress and Market Potential for MiNK Therapeutics’ agenT-797 in Gastric Cancer StudyMarch 21, 2024 | investorplace.comINKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023March 21, 2024 | globenewswire.comMiNK Reports Fourth Quarter and Year-End 2023 ResultsMarch 20, 2024 | benzinga.comEarnings Outlook For MiNK TherapeuticsMarch 8, 2024 | finanznachrichten.deMiNK Therapeutics: MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024March 7, 2024 | globenewswire.comMiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial ReportMarch 6, 2024 | globenewswire.comMiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024February 24, 2024 | msn.comCell therapy could help patients with ARDS from severe Covid-19, study involving ARU showsFebruary 14, 2024 | finance.yahoo.comFirst Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and BalstilimabFebruary 6, 2024 | finance.yahoo.comMiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature CommunicationsJanuary 30, 2024 | finance.yahoo.comMiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in OncogeneDecember 20, 2023 | markets.businessinsider.comImmunoScape, MiNK Therapeutics Join To Develop Next-generation TCR TherapiesDecember 20, 2023 | finance.yahoo.comImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic DevelopmentNovember 22, 2023 | morningstar.comMiNK Therapeutics Inc INKTNovember 9, 2023 | msn.comMiNK Therapeutics GAAP EPS of -$0.15November 9, 2023 | finance.yahoo.comMiNK Therapeutics Reports Third Quarter 2023 ResultsNovember 9, 2023 | finance.yahoo.comMiNK Therapeutics Inc (INKT) Reports Q3 2023 Results: Clinical Progress Amid Financial ChallengesNovember 3, 2023 | finance.yahoo.comMiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023November 3, 2023 | finance.yahoo.comMiNK Therapeutics Insider Ups Holding During YearOctober 30, 2023 | finance.yahoo.comMiNK to Provide Third Quarter 2023 Financial Report and Corporate UpdateSeptember 27, 2023 | finance.yahoo.comMiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023September 23, 2023 | finance.yahoo.comCan MiNK Therapeutics (NASDAQ:INKT) Afford To Invest In Growth?August 24, 2023 | finance.yahoo.comMiNK Therapeutics to Participate in September Investor ConferencesAugust 23, 2023 | msn.comMiNK Therapeutics: In The Very Early Days Of A Big HuntAugust 10, 2023 | nl.investing.comMink Therapeutics winst hoger dan voorspeld, omzet volgens verwachtingAugust 10, 2023 | finance.yahoo.comMiNK Therapeutics Reports Second Quarter 2023 ResultsJuly 28, 2023 | finance.yahoo.comMiNK to Provide Second Quarter 2023 Financial Report and Corporate UpdateMay 23, 2023 | cbsnews.com"Off-the-shelf" cell therapy shows promise for cancers resistant to current treatments, including immunotherapiesMay 22, 2023 | finance.yahoo.comMiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International ConferenceMay 18, 2023 | markets.businessinsider.comB.Riley Financial Sticks to Their Buy Rating for MiNK Therapeutics (INKT)May 18, 2023 | finance.yahoo.comMiNK's Novel FAP-CAR-iNKT Presented at ASGCTMay 15, 2023 | markets.businessinsider.comRobert W. Baird Reaffirms Their Buy Rating on MiNK Therapeutics (INKT)May 12, 2023 | msn.comRecap: MiNK Therapeutics Q1 EarningsMay 12, 2023 | msn.comThe Latest Analyst Ratings for MiNK TherapeuticsMay 12, 2023 | markets.businessinsider.comMiNK Therapeutics (INKT) Has a New Rating from H.C. WainwrightMay 12, 2023 | markets.businessinsider.comB.Riley Financial Keeps Their Buy Rating on MiNK Therapeutics (INKT)May 11, 2023 | finance.yahoo.comMiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address The #1 Crypto That You Don’t Own… Yet (Ad)There’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening. Click here for all the details… INKT Media Mentions By Week INKT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INKT News Sentiment▼0.440.81▲Average Medical News Sentiment INKT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INKT Articles This Week▼20▲INKT Articles Average Week Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Celularity News Today Adicet Bio News Today Sangamo Therapeutics News Today Vigil Neuroscience News Today aTyr Pharma News Today Omega Therapeutics News Today DBV Technologies News Today bluebird bio News Today Athira Pharma News Today Cognition Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INKT) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyOn June 10, Nvidia makes its next big moveWeiss RatingsUnlock Explosive Gains with This Defense StockBehind the MarketsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProThe Worst is Yet to Come…Porter & CompanyDems have chosen Biden replacement?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
